



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		RECEIVED	
		Page 3	of
		Attorney Docket Number	17682A-007400US

U.S. PATENT DOCUMENTS					
Examiner	Cite No. ¹	Document Number Number Kind Code ² (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A	US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials ⁴	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ Kind Code ⁴ (If Known)		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ⁴	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
MCH	B	SEELA ET AL. "Oligonucleotides Containing Pyrazolo(3,4-d) pyrimidines: The Influence of 7-Substituted 8-Aza-7-deaza-2-deoxyguanosine on the Duplex Structure and Stability" HELVETICA ACTA, (1999) Vol. 82, Pages 1640-1650.			
MCH	C	SEELA ET AL. "Alternating d(G-C)3 and d(C-G)3 Hexanucleotides containing 7-deaza-2-deoxyguanosine or 8-Aza-7-deaza-2-deoxyguanosine in place of dG" NUCLEIC ACID RESEARCH (1989), Vol. 17, No. 3, Pages 893-910.			
MCH	D	SEELA ET AL. "8-Aza-7-deaza-2-deoxyguanosine" Phosphoramidite Synthesis and Properties of Octanucleotides" HELVETICA CHIMICA ACTA, (1988) Vol. 71, Pages 1191-1198.			

Examiner Signature		Date Considered	12/16/04
-----------------------	--	--------------------	----------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO in process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.
DE 7108898 v1